Sidoti Lowers Heska Corp. (HSKA) to Neutral
Sidoti downgraded shares of Heska Corp. (NASDAQ:HSKA) from a buy rating to a neutral rating in a research note issued to investors on Monday morning. They currently have $71.00 target price on the stock.
HSKA has been the topic of a number of other research reports. B. Riley downgraded shares of Heska Corp. from a buy rating to a neutral rating and increased their price target for the stock from $52.50 to $53.00 in a research note on Wednesday, September 21st. Zacks Investment Research downgraded shares of Heska Corp. from a buy rating to a hold rating in a research note on Thursday, October 20th. Finally, Gabelli downgraded shares of Heska Corp. from a buy rating to a hold rating in a research note on Thursday, August 4th. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The company presently has a consensus rating of Buy and a consensus target price of $66.88.
Heska Corp. (NASDAQ:HSKA) opened at 66.11 on Monday. The firm has a market cap of $456.03 million, a P/E ratio of 52.93 and a beta of 0.74. The company’s 50 day moving average is $58.16 and its 200-day moving average is $48.46. Heska Corp. has a 52 week low of $26.25 and a 52 week high of $69.80.
Heska Corp. (NASDAQ:HSKA) last posted its quarterly earnings results on Tuesday, November 1st. The company reported $0.45 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.25 by $0.20. The company had revenue of $33.40 million for the quarter, compared to the consensus estimate of $31.36 million. Heska Corp. had a net margin of 7.55% and a return on equity of 10.46%. The company’s quarterly revenue was up 19.3% on a year-over-year basis. Equities analysts expect that Heska Corp. will post $1.32 earnings per share for the current year.
In related news, CFO John Mcmahon sold 1,999 shares of the firm’s stock in a transaction on Monday, November 28th. The shares were sold at an average price of $65.64, for a total transaction of $131,214.36. Following the completion of the sale, the chief financial officer now directly owns 584 shares of the company’s stock, valued at approximately $38,333.76. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Rod Lippincott sold 5,000 shares of the firm’s stock in a transaction on Tuesday, November 22nd. The shares were sold at an average price of $64.85, for a total transaction of $324,250.00. Following the sale, the executive vice president now directly owns 10,192 shares of the company’s stock, valued at $660,951.20. The disclosure for this sale can be found here. 15.30% of the stock is currently owned by insiders.
Large investors have recently added to or reduced their stakes in the stock. MSI Financial Services Inc purchased a new stake in Heska Corp. during the third quarter worth $103,000. Bank of Montreal Can purchased a new stake in Heska Corp. during the second quarter worth $128,000. Acrospire Investment Management LLC raised its stake in Heska Corp. by 786.3% in the second quarter. Acrospire Investment Management LLC now owns 4,396 shares of the company’s stock worth $163,000 after buying an additional 3,900 shares during the last quarter. The Manufacturers Life Insurance Company purchased a new stake in Heska Corp. during the third quarter worth $242,000. Finally, Two Sigma Securities LLC purchased a new stake in Heska Corp. during the third quarter worth $244,000. 72.70% of the stock is owned by institutional investors and hedge funds.
Heska Corp. Company Profile
Heska Corporation develops, manufactures, markets, sells and supports veterinary products. The Company focuses on the canine and feline companion animal health markets. Its segments include Core Companion Animal Health segment, which includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, and single use products and services, such as heartworm diagnostic tests, heartworm preventive products, allergy immunotherapy products and allergy testing, and Other Vaccines, Pharmaceuticals and Products segment, which includes private label vaccine and pharmaceutical production, primarily for cattle but also for other animals, including small mammals.
Receive News & Ratings for Heska Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska Corp. and related companies with MarketBeat.com's FREE daily email newsletter.